PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward EnrollmentSHIELD Phase 2 Study: first payment made under the clinical trial agreement with Mount Sinai and study drug ordered; the randomized, double-blind, placebo-controlled study, registered as NCT07597902, plans to enroll approximately 150 adults
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic IllnessesTUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company as a leading developer of treatments for Long COVID and a broad range of infection-associated chronic illnesses (IACI), a rapidly emerging global healthcare challenge representing a significant and growing market opportunity.
PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID ProgramTUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long COVID, today announced two major milestones supporting the advancement of its planned SHIELD Study, a randomized, double-blind, placebo-controlled Phase 2 Long COVID clinical study. This study will be conducted in collaboration with the Icahn School of Medicine at Mount Sinai under the leadership of David Putrino, PhD, with Amy Proal, PhD.
PridCor Therapeutics Principal Investigator Dr. David Putrino Participates in National Long COVID Roundtable Convened by Secretary Robert F. Kennedy Jr.TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) -- PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated in a national roundtable on Long COVID convened by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. The event brought together leading researchers, clinicians, and policymakers to discuss urgent priorities for advancing diagnosis, treatment, and care for millions of Americans living with Long COVID.
PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen-New Preprint: PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC) who were given a continuous regimen of 120-days of valacyclovir and celecoxib with a pulsed 15-day treatment of Paxlovid (combination antiviral treatment, or CAR), and these patients were compared to 12 patients with Long COVID who received the 120-day valacyclovir and celecoxib protocol only. This CAR appeared superior to the valacyclovir and celecoxib combination in improving self-reported fatigue, dysautonomia and brain fog in these LC patients.
